Novel skeletal derivative effective for her2 mutation, and pharmaceutical composition comprising same

WO2025063725A1 Publication Date: 2025-03-27HANMI PHARM CO LTD

4 Cites 0 Cited by

Patent Information

Application Number: PCT/KR2024/014156
Authority / Receiving Office: WO · WO
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-01-30
Filing Date: 2024-09-20
Publication Date: 2025-03-27

Application Information

Patent Timeline

30 Jan 2024

Priority

20 Sep 2024

Application

PCT/KR2024/014156

27 Mar 2025

Publication

WO2025063725A1

IPC: C07D471/04; A61K31/519; A61K31/4709; A61K31/517; A61P35/00; C07D487/04; C07D403/14; C07D403/12

CPC: A61K31/4709; A61K31/517; A61K31/519; A61P35/00; C07D403/12; C07D403/14; C07D471/04; C07D487/04

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

AI Tagging

Application Domain

Organic active ingredients Organic chemistry

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

A compound defined by chemical formula 1, a stereoisomer thereof, a tautomer thereof, and a pharmaceutically acceptable salt thereof are provided. The compound of the present invention can inhibit the activity of HER2 kinase. In chemical formula 1, R1 to R3, A1 to A4, L1, E, Z and n are the same as those defined in the present specification.

Need to check novelty before this filing date? Find Prior Art